Skip to main content

Table 3 Effects of respiratory tests on the change in VC in Pirfenidone and Placebo groups

From: Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment

Group

Parameter

Estimate

S.E.

t-value

p-value

Pirfenidone

Intercept

-0.3543

0.7428

-0.48

0.6340

(n = 155)

The lowest SpO2

0.0029

0.0091

0.32

0.7514

 

%VC

0.0035

0.0011

3.17

0.0018

 

%DLco

-0.0011

0.0011

-0.97

0.3361

 

PaO2

-0.0025

0.0021

-1.19

0.2378

Placebo

Intercept

-2.0951

1.2726

-1.65

0.1029

(n = 102)

The lowest SpO2

0.0217

0.0146

1.48

0.1412

 

%VC

0.0008

0.0017

0.49

0.6279

 

%DLco

-0.0017

0.0017

-0.99

0.3248

 

PaO2

0.0003

0.0033

0.10

0.9172

  1. (%TLC was omitted from the evaluation)
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us